Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic cuts costs

This article was originally published in The Gray Sheet

Executive Summary

Planned elimination of 900 positions is part of an ongoing restructuring effort aimed at saving $125 million annually and is expected to be complete by next April, the firm discloses in a Sept. 5 10-Q filing with the Securities and Exchange Commission. The reductions in force, of which about 350 had been achieved as of July 27, will include early retirements, and voluntary and involuntary separations. The effort, which began earlier this year, includes driving manufacturing efficiencies in the firm's cardiovascular business, downsizing its Physio-Control external defibrillator unit and rebalancing resources in its cardiac rhythm disease management business "in response to current market dynamics," the firm explains (1"The Gray Sheet" Aug. 27, 2007, p. 4)...

You may also be interested in...



Medtronic Prestige Cervical Disc Rollout Marks 800 Surgeons Trained To Date

Medtronic has trained over 800 surgeons to date on the use of its Prestige artificial cervical disc and will train 200 more each weekend "for the next several weeks," the firm reported Aug. 21 during its fiscal 2008 first quarter earnings call

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel